Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This cannabis-infused oil is an investigational drug product containing a combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) in specific ratios, primarily 25:1 and 5:1. Developed by St. Joseph's Healthcare Hamilton in collaboration with McMaster University, it is being evaluated in a Phase 2 clinical trial (NCT05041647) for the treatment of insomnia in adults with major depressive disorder (MDD). The formulation leverages the therapeutic properties of CBD, a non-intoxicating cannabinoid with potential anxiolytic and sedative effects, and low-dose THC, which may enhance efficacy through the entourage effect. The study aims to assess the safety and efficacy of high-dose (50 mg/mL) versus low-dose (10 mg/mL) CBD concentrations in improving sleep parameters such as sleep latency and wake after sleep onset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabidiol + tetrahydrocannabinol (St. Joseph's Healthcare Hamilton).